Immuno-Oncology Biomarkers 2010 and Beyond

Biomarkers Main Page  |  Highlights |  Program Purpose  |  Presentation Slides & Schedule |  Faculty
NIH Campus Info  |  Preliminary Program  |  Photos  | Resource Document and Published Summary

Biomarkers Main Page  |  Highlights |  Program Purpose  |  Presentation Slides & Schedule |  Faculty
NIH Campus Info  |  Preliminary Program  |  Photos  | Resource Document and Published Summary

September 30, 2010
Masur Auditorium on the NIH Campus
Bethesda, MD

Program Schedule
To view slides from a presenter click the icon next to the presentation title.

Thursday, September 30, 2010
8:00 am - 8:05 am	Welcome and Introduction Francesco Marincola, MD - National Institutes of Health (CC, DTM)
8:05 am - 8:20 am	Defining the Critical Hurdles in Cancer Immunotherapy Bernard A. Fox, PhD - Earle A. Chiles Research Institute
8:20 am - 8:30 am	Priorities in Biomarkers Development in Immunotherapy Samir N. Khleif, MD – Vaccine Branch NCI, NIH
8:30 am - 9:45 am	Session 1: Immunologic Monitoring: Standardization and Validation of Assays Chair: Lisa H. Butterfield, PhD - University of Pittsburgh Recommendations from the iSBTc/FDA/NCI Workshop on Immunotherapy Biomarkers Lisa H. Butterfield, PhD – University of Pittsburgh CTL on ELISPOT Standardization, Story of Successful Standardization Paul V. Lehmann, MD, PhD – Cellular Technology Limited Harmonization of Immunologic Monitoring Across Institutions Cedrik M. Britten, MD – Association for Cancer Immunotherapy (CIMT) Panel Discussion Panelists: Session 1 Speakers: Sylvia Janetzki, MD - ZellNet Consulting, Inc. and Cancer Immunotherapy Consortium; and Michael Kalos, PhD - University of Pennsylvania
10:00 am - 12:00 pm	Session 2: Correlation of Immunity to Clinical Response and Potency Assays Chair:  Mary L. (Nora) Disis, MD - University of Washington Regulatory and Scientific Considerations for Potency Testing and Immune Monitoring Raj K. Puri, MD, PhD – U.S. Food and Drug Administration (CBER) Immunologic Biomarkers as Correlates for Clinical Response Mary L. (Nora) Disis, MD – University of Washington Measuring the Potency of Dendritic Cell Preparations Using Transcriptional Analysis David Stroncek, MD – National Institutes of Health Sipuleucel-T Immune Parameters and Correlation with Overall Survival Mark W. Frohlich, MD – Dendreon Corporation Panel Discussion Panelists: Session 2 Speakers; Leif Håkansson, MD, PhD - Biotherapy Development Association; and Nicholas P. Restifo, MD - National Cancer Institute
1:15 pm - 3:00 pm	Session 3: Novel Methodologies for Assessing the Immune Landscape: Clinical Utility of Novel Technologies Co-Chairs:  Francesco Marincola, MD - National Institutes of Health (CC, DTM)              Peter P. Lee, MD - Stanford University Genetic Variants in IL28B (IFN-λ): Major Predictors of Response to IFN-alfa Therapy for Chronic Hepatitis C Thomas R. O’Brien, MD – National Cancer Institute, Division of Cancer Epidemiology and Genetics A Critical Concentration of Cytolytically Active, Tumor Antigen-Specific CD8+T-Cells Is Required to Control Growth of Cognate Antigen-Expressing Tumor Cells In Vitro and In Vivo Samuel C. Silverstein, MD – Columbia University Immune Biomarkers: A Novel Paradigm for Cancer Jérôme Galon, PhD – INSERM, Integrative Cancer Immunology Laboratory, Cordeliers Research Center Immune Changes in Tumor-Draining Lymph Nodes as Novel Biomarkers Peter P. Lee, MD – Stanford University Panel Discussion Panelists: Session 3 Speakers; Co-Chairs and Aniruddha (Raja) Choudhury, PhD Nordic Center for Development of Antitumor Vaccines, NCV-network
3:15 pm - 4:45 pm	Session 4: Recommendations on Incorporation of Biomarkers into the Clinical Arena Chair:  John M. Kirkwood, MD - University of Pittsburgh Cancer Institute Single Cell Network Profiling Technology and Applications in Immunological Monitoring Diane Longo, PhD – Nodality Inc. Biostatistical Considerations: Biologics and Biomarkers in Oncology Daniel Normolle, PhD – University of Pittsburgh Cancer Institute Prospects for New Clinical Flow Cytometry Assays Holden T. Maecker, PhD – Stanford University Medical Center Predictive Biomarkers for Tumor Immunotherapy: Are We Ready for Clinical Implementation? Howard L. Kaufman, MD, FACS – Rush University Medical Center
4:45 pm - 5:00 pm	Summary and Conclusions of the Biomarkers Symposium Lisa H. Butterfield, PhD - University of Pittsburgh
Friday, October 1
8:00 am - 5:00 pm	Workshop on Monoclonal Antibodies in Cancer For more information, please click here.
8:00 am - 5:00 pm	Primer on Tumor Immunology and Biological Therapy of Cancer For more information, please click here.
Saturday, October 2 - Monday, October 4
iSBTc 25th Annual Meeting    For more information, please click here.

All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.